Table 3.
Previous meta-analyses on the thromboembolic risk with bevacizumab in various tumor types.
| Author, Year [Ref] |
Tumor Types | Total Included Patients | All TE RR (95% CI) |
VTE RR (95% CI) |
ATE RR (95% CI) |
|---|---|---|---|---|---|
| Scappaticci, 2007 [44] |
Lung, colorectal, breast | 1745 | NA | 0.89 (0.66–1.20) p = 0.44 |
1.8 (0.94–3.33) p = 0.076 |
| Nalluri, 2008 [45] |
Lung, colorectal, breast, renal, pancreatic |
7956 | NA | 1.33 (1.13–1.56) p < 0.001 |
NA |
| Ranpura, 2010 [49] |
Lung, colorectal, breast, renal, pancreatic |
12,617 | NA | NA | 1.44 (1.08–1.91) p = 0.013 |
| Azzi, 2010 [50] |
not specified | 13,026 | NA | NA | 1.46 (1.11–1.93) p = 0.007 |
| Hurwitz, 2011 [54] |
Lung, colorectal, breast, renal, pancreatic |
6055 | NA | 0.91 (0.77–1.06) p = 0.23 |
NA |
| Cortes, 2012 [51] |
breast | 3784 | NA | 1.02 (0.70–1.61) p = 0.78 |
1.49 (0.70–3.19) p = 0.30 |
| Totzeck, 2017 [52] |
Lung, colorectal, breast, renal, ovarian, gastric |
20,500 | NA | 1.29 (1.13–1.48) p = 0.0001 |
1.37 (1.10–1.70) p = 0.004 |
| Li, 2018 [53] |
lung | 3555 | 1.74 (1.15–2.62) p = 0.008 |
NA | NA |
VTE: venous thromboembolism; ATE: arterial thromboembolism; RR: risk ratio; CI: confidence interval; NA: not available.